VEGFA and nonpapillary renal cell carcinoma: In addition to bevacizumab, multiple other combinations of anti-VEGF TKI and ICI regimens have found clinical success particularly in the first line ccRCC setting, with subsequent regulatory approval (see Table 1, Figure 1).